Ten-X Genomics Shares Drop After Citigroup Downgrade
Update: 2025-12-11
Description
Ten-X Genomics shares plummeted by six point three percent today, following Citigroups downgrade from Buy to Neutral. Despite keeping the price target unchanged, this change led to a significant market reaction. The companys shares are known for volatility, with over fifty moves of more than five percent in the past year. Meanwhile, other healthcare companies saw a positive impact from potential insurance subsidy extensions, with Centene, Molina Healthcare, and Oscar Health experiencing significant gains. Despite todays dip, Ten-X Genomics is still up sixteen point three percent this year, but trades eighteen percent below its fifty-two-week high.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
